The Latest Breaking News from JP Morgan

JP Morgan boss: US should take stronger stance over Russia

Jamie Dimon says bank could lose $1bn from crisis and calls for new ‘Marshall plan’ to ensure energy supply

The Guardian - UK · Apr 4, 2022

JP Morgan Drops Apple, Qualcomm from Top Picks as Tech Demand Slows

Slowing demand for smartphones is likely to hit growth at Apple and chipmaker Qualcomm, analysts at J.P.

Asharq Al-Awsat · Apr 1, 2022

What's Going On With Caterpillar Shares?

Caterpillar Inc. (NYSE: CAT) shares are trading lower by 1.64% at $219.17 Friday afternoon on average volume. It was a quiet week for the industrial giant. JP Morgan analyst Tami Zakaria maintained Caterpillar on Monday with an Overweight and raised the price target from $241 to $257. 

Benzinga · Apr 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022

Upgrades

Benzinga · Mar 28, 2022

UK's 'best' savings account launches paying 1.5% interest and cashback on top

The Chase account allows savers to pay in up to £250,000 in total and access their savings as often as they like, with no penalty fees, charges or loss of interest

Daily Mirror · Mar 28, 2022

JP Morgan’s digital bank Chase launches 1.5% saver as rate rise sparks battle for cash

Interest on the new savings account is double the current Bank Of England base rate

Evening Standard · Mar 28, 2022

Sir Chris Hohn urges shareholders to vote against ‘greenwashing’ bank directors

Call comes as thinktank says the world’s 30 largest financial institutions are undermining their net zero targets

The Guardian - UK · Mar 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

Upgrades

Benzinga · Mar 24, 2022

How second-chance employment combats the ‘scarlet letter’ of a criminal record during the hiring process

About a third of adult Americans have a criminal record. A new generation of companies say that shouldn’t stop them from getting jobs, Josh Marcus writes

The Independent UK · Mar 22, 2022

80 Biggest Movers From Yesterday

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-1010 for the treatment of advanced solid tumors.

Benzinga · Mar 17, 2022